| Date |
Research Question / Title |
Unique ID |
Research Team |
|
June 7, 2022
|
What is the efficacy of a 4th booster dose for COVID-19?
|
EOC220304v002 RR
|
EOC
|
|
June 6, 2022
|
What is known about hybrid immunity to COVID-19?
|
INF220501 RR Table
|
Infectious Disease
|
|
June 6, 2022
|
What is known about hybrid immunity to COVID-19?
|
INF220501 RR
|
Infectious Disease
|
|
March 10, 2022
|
What is the safety/efficacy of the Novavax COVID-19 vaccine?
|
EOC220302 RR Table
|
EOC
|
|
March 10, 2022
|
What is the safety/efficacy of the Novavax COVID-19 vaccine?
|
EOC220302 RR
|
EOC
|
|
December 26, 2021
|
How effective are COVID-19 vaccines?
|
INF031801v019 RR Table
|
Infectious Disease
|
|
December 26, 2021
|
How effective are COVID-19 vaccines? [Evergreen]
|
INF031801v019 RR
|
Infectious Disease
|
|
January 22, 2021
|
What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update]
|
EOC062201v2 RR
|
EOC
|
|
January 22, 2021
|
What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update]
|
EOC062201v2 RR Table
|
EOC
|
|
November 2, 2020
|
What is the risk of reinfection from COVID-19? [Update]
|
EOC032401v3 RR
|
EOC
|
|
May 19, 2020
|
What is the relationship between antibody development and viral shedding and infectiousness? [Update]
|
LAB041601v2 RR
|
Laboratory
|
|
May 8, 2020
|
What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update]
|
LAB040701v2 RR
|
Laboratory
|
|
April 27, 2020
|
What is the period of communicability of symptomatic SARS-CoV-2?
|
INF042401 RR
|
Infectious Disease
|
|
April 15, 2020
|
At what time in the disease timeline of COVID-19 do antibodies develop?
|
LAB041402 RR
|
Laboratory
|
|
April 11, 2020
|
Is the IgM or IgG immune response protective?
|
LAB040803 RR
|
Laboratory
|
|
June 7, 0222
|
What is the efficacy of a 4th booster dose for COVID-19?
|
EOC220304v002 RR Table
|
EOC
|
